The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...

The global sleep apnea devices market is set to expand at a steady CAGR of 9.5%, growing from USD 8.2 billion in 2023 to USD ...

CPAP therapy, the traditional standard for obstructive sleep apnea (OSA), is universally despised by patients, resulting in abysmally low compliance rates. Recent studies show it also fails to ...

According to statistics by the American Association of Medicine, the disorder sleep apnea affects approximately 30 million US ...

Taking a GLP-1 may help treat sleep apnea since obesity is one of many factors that increases your likelihood of the sleep ...

For patients with obstructive sleep apnea (OSA), sleep surgery is associated with a significantly reduced risk for mo ...

Persistent weakness despite adequate rest can be caused by various medical conditions such as diabetes, thyroid disorders, ...

A new study conducted by researchers from Charles University (Prague, Czech Republic) has uncovered a significant LINK between obstructive sleep apnea syndrome and increased mortality among ...

Sleep is essential for your overall health, but it plays an especially important role in protecting your brain. Research has ...

Key Takeaways Untreated sleep apnea contributes to car crashesPatients who got no treatment were 21% more likely to be in a ...

The global anti-snoring devices market, valued at US$ 0.83 billion in 2023, is forecasted to grow at a robust CAGR of 9.8%, reaching US$ 0.91 ...

The global anti-snoring devices market, valued at US$ 0.83 billion in 2023, is forecasted to grow at a robust CAGR of 9.8%, reaching US$ ...